Results 51 to 60 of about 5,265 (145)

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. [PDF]

PLoS Neglected Tropical Diseases, 2019
Yellow fever virus (YFV) is a member of the Flaviviridae family. In Brazil, yellow fever (YF) cases have increased dramatically in sylvatic areas neighboring urban zones in the last few years. Because of the high lethality rates associated with infection
Caroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, André C Ferreira, Patrícia A Reis, Rodrigo Delvecchio, Fabio L Monteiro, Giselle Barbosa-Lima, Harrison James Westgarth, Yasmine Rangel Vieira, Mayara Mattos, Natasha Rocha, Lucas Villas Bôas Hoelz, Rennan Papaleo Paes Leme, Mônica M Bastos, Gisele Olinto L Rodrigues, Carla Elizabeth M Lopes, Celso Martins Queiroz-Junior, Cristiano X Lima, Vivian V Costa, Mauro M Teixeira, Fernando A Bozza, Patrícia T Bozza, Nubia Boechat, Amilcar Tanuri, Thiago Moreno L Souza   +25 more
doaj   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1338-1347, November 2026.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir [PDF]

, 2019
Background & Aims: Sofosbuvir is a frequently used pan-genotype inhibitor of hepatitis C virus (HCV) polymerase. This drug eliminates most chronic HCV infections and resistance-associated substitutions in the polymerase are rare.
McLauchlan, J, Jones, M, Wing, Peter A.C., Smith, D, Aranday-Cortes, Elihu, DaSilva, Sampath, Da Silva Filipe, Ana, Bamford, C, Cunningham, M, Jason Lee, Wing-Liu, Filipe, ADS, Cheung, Michelle, Foster, Graham R., Lee, W-YJ, Irving, W, Barnes, E, McLauchlan, John, Bamford, Connor, Aranday-Cortes, E, Ansari, A, Barnes, Eleanor, Cunningham, Morven, Smith, David, Ansari, Azim, Jones, Meleri, Cheung, M, Foster, GR, Irving, William, Wing, PAC, Cunningham, Morvan, Lee, Wing-Yiu Jason, DaSilva, S   +31 more
core   +1 more source

Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).

, 2021
Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).
Kuntjoro Harimurti (10035887), Evy Yunihastuti (428215), Andri Sanityoso Sulaiman (10881067), Rahmat Hariyanto (11268731)   +3 more
core   +1 more source

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Diseases
Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, Tawanda Chivese   +10 more
doaj   +1 more source

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir

Journal of Investigative Medicine High Impact Case Reports, 2015
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes ...
Resmi Premji MD, Nira Roopnarinesingh MD, Nazia Qazi MD, Eric S Nylen MD   +3 more
doaj   +1 more source

Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. [PDF]

PLoS ONE, 2015
In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of sofosbuvir-based treatment compared to current standard treatment in ...
Alena M Pfeil, Oliver Reich, Ines M Guerra, Sandrine Cure, Francesco Negro, Beat Müllhaupt, Daniel Lavanchy, Matthias Schwenkglenks   +7 more
doaj   +1 more source

Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial

Journal of Viral Hepatitis, Volume 33, Issue 11, November 2026.
ABSTRACT The introduction of potent, well‐tolerated direct‐acting antivirals (DAAs) has transformed hepatitis C virus (HCV) therapy and spurred global elimination efforts. However, the extensive genetic diversity of HCV may affect antiviral efficacy, particularly in low and middle‐income regions where limited data currently exist.
Win Min Han, Sunil Solomon, Sandra Wagner‐Cardoso, Jiani Li, Aiyappa Parvangada, Mark Sulkowski, Susanna Naggie, Ross Martin, Hongmei Mo, Evguenia Maiorova, David Wyles, the ACTG A5360 study team   +11 more
wiley   +1 more source

Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
Many pathophysiological pathways associated with cardiovascular diseases involve multiple drug targets. This article reviews recent advances in the development of pharmacological compounds capable of simultaneously modulating multiple mechanisms. Multitarget drugs offer a promising therapeutic approach for complex cardiovascular disorders, including ...
Gyuzel Y. Mitronova, Vladimir N. Belov, Constanze Schmidt, Stephan E. Lehnart   +3 more
wiley   +1 more source

Comparison of nominal and PPP-adjusted prices of sofosbuvir and ledipasvir/sofosbuvir.

, 2016
Fig 1 shows the nominal (USD FOREX) and PPP-adjusted (USD PPP) prices of (A) sofosbuvir and (B) ledipasvir/sofosbuvir, with and without a 23% rebate (or price reduction).
Peter Beyer (21528), Kees de Joncheere (3166164), Stefan Wiktor (3166158), Kiu Tay-Teo (3166161), Swathi Iyengar (3166167), Sabine Vogler (3131850), Suzanne Hill (160643)   +6 more
core   +1 more source